PCM
BCRX icon

Prelude Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Prelude Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200
Closed -$1K – 1831
2020
Q2 		$1K Buy
+200
New +$799 ﹤0.01% 1860

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's BCRX Position: Q3 2025 in Review

Prelude Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 60,897 shares — an estimated $546K sold.

Prelude Capital Management first reported a position in BCRX in Q2 2014 and held it in 13 quarters. The position peaked at $749K in Q1 2025. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Prelude Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 60,897 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $546K.
  • Prelude Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 13 quarters.
  • Prelude Capital Management's BioCryst Pharmaceuticals position peaked at $749K in Q1 2025.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.